<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35236203</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes.</ArticleTitle>
        <Pagination>
          <StartPage>702</StartPage>
          <EndPage>713</EndPage>
          <MedlinePgn>702-713</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2044937</ELocationID>
        <Abstract>
          <AbstractText>Prostate cancer (PCa) responds poorly to routine immunotherapy due to the tumor immunosuppressive microenvironment. Here, we describe an ultrasound-based drug delivery strategy to stimulate potent anti-tumor immunity via exosomes encapsulated with sonosensitizers Chlorin e6 (Ce6) and immune adjuvant R848, namely Exo<sup>Ce6+R848</sup>. Exo<sup>Ce6+R848</sup> was constructed by simple co-incubation of Ce6 and R848 with HEK 293T cell-derived exosomes. The properties of exosomes were not affected after loading Ce6 and R848, and the exosomes were accumulated in the tumor site after intratumoral injection. <i>In vitro</i> and <i>in vivo</i> assays showed that ultrasonic irradiation enhanced R848-mediated DCs maturation when Exo<sup>Ce6+R848</sup> was engulfed by DCs, as demonstrated by the upregulated expression of CD80 and CD86. Furthermore, these engineered exosomes together with ultrasound irradiation could synergistically reprogram macrophages from an immunosuppressive M2-like phenotype to an anti-tumor M1-like phenotype, further activating effector T cells and reverting the immunosuppressive microenvironment. The exosome delivery strategy not only supplies a paradigm for overcoming side effects of systemic delivery of Ce6 and R848, but also offers an effective combination regimen of cancer immunotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Dingyi</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Zhuo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi' an, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jianmei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Medicine, The Fourth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yunnan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, Tangdu Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-6882-4044</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        <Keyword MajorTopicYN="N">exosomes</Keyword>
        <Keyword MajorTopicYN="N">immunoadjuvant</Keyword>
        <Keyword MajorTopicYN="N">sonodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">synergistic effect</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35236203</ArticleId>
        <ArticleId IdType="pmc">PMC8903759</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2044937</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alam MM, Yang D, Trivett A, et al.  (2018). HMGN1 and R848 synergistically activate dendritic cells using multiple signaling pathways. Front Immunol
9:2982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6305469</ArticleId>
            <ArticleId IdType="pubmed">30619338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonarakis ES, Piulats JM, Gross-Goupil M, et al.  (2020). Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol
38:395–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7186583</ArticleId>
            <ArticleId IdType="pubmed">31774688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bansal D, Reimers MA, Knoche EM, et al.  (2021). Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer. Cancers
13:334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7831137</ArticleId>
            <ArticleId IdType="pubmed">33477569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batrakova EV, Kim MS. (2015). Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release
219:396–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4656109</ArticleId>
            <ArticleId IdType="pubmed">26241750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Song Y, Du W, et al.  (2019). Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci
26:78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6800990</ArticleId>
            <ArticleId IdType="pubmed">31629410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsharkasy OM, Nordin JZ, Hagey DW, et al.  (2020). Extracellular vesicles as drug delivery systems: why and how?
Adv Drug Deliv Rev
159:332–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32305351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grassi F, Tell G, Robbie-Ryan M, et al.  (2007). Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci U S A
104:15087–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1986617</ArticleId>
            <ArticleId IdType="pubmed">17848519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrmann IK, Wood MJA, Fuhrmann G. (2021). Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol
16:748–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34211166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu M, Zhang J, Yu Y, et al.  (2020). Injectable liquid crystal formation system for reshaping tumor immunosuppressive microenvironment to boost antitumor immunity: postoperative chemoimmunotherapy. Small
16:e2004905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33206460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Teng XL, Zhang T, et al.  (2021). SENP3 senses oxidative stress to facilitate STING-dependent dendritic cell antitumor function. Mol Cell
81:940–52.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33434504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Xiao Z, An Y, et al.  (2021). Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy. Biomaterials
269:120636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33453632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jhunjhunwala S, Hammer C, Delamarre L. (2021). Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer
21:298–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33750922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuppner MC, Gastpar R, Gelwer S, et al.  (2001). The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol
31:1602–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11465118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon ED, Drake CG, Scher HI, et al.  (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol
15:700–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4418935</ArticleId>
            <ArticleId IdType="pubmed">24831977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Zhao Z, Qin X, et al.  (2021). A checkpoint-regulatable immune niche created by injectable hydrogel for tumor therapy. Adv Funct Mater
31:2104630.</Citation>
        </Reference>
        <Reference>
          <Citation>McHale AP, Callan JF, Nomikou N, et al.  (2016). Sonodynamic therapy: concept, mechanism and application to cancer treatment. Adv Exp Med Biol
880:429–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26486350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michaelis KA, Norgard MA, Zhu X, et al.  (2019). The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat Commun
10:4682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6794326</ArticleId>
            <ArticleId IdType="pubmed">31615993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nezhadi S, Saadat E, Handali S, et al.  (2021). Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities. J Drug Target
29:185–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32772739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paardekooper LM, Vos W, van den Bogaart G. (2019). Oxygen in the tumor microenvironment: effects on DC function. Oncotarget
10:883.– .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6368231</ArticleId>
            <ArticleId IdType="pubmed">30783517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pathria P, Louis TL, Varner JA. (2019). Targeting tumor-associated macrophages in cancer. Trends Immunol
40:310–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30890304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patil SM, Sawant SS, Kunda NK. (2020). Exosomes as drug delivery systems: a brief overview and progress update. Eur J Pharm Biopharm
154:259–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32717385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng Y, Jia L, Wang S, et al.  (2018). Sonodynamic therapy improves anti-tumor immune effect by increasing the infiltration of CD8+ T cells and altering tumor blood vessels in murine B16F10 melanoma xenograft. Oncol Rep
40:2163–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30106435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfirschke C, Siwicki M, Liao H-W, et al.  (2017). Tumor microenvironment: no effector T cells without dendritic cells. Cancer Cell
31:614–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28486102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poh AR, Ernst M. (2018). Targeting macrophages in cancer: from bench to bedside. Front Oncol
8:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5858529</ArticleId>
            <ArticleId IdType="pubmed">29594035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pullan JE, Confeld MI, Osborn JK, et al.  (2019). Exosomes as drug carriers for cancer therapy. Mol Pharm
16:1789–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30951627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Runcie KD, Dallos MC. (2021). Prostate cancer immunotherapy—finally in from the cold?
Curr Oncol Rep
23:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34125308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid D, Park CG, Hartl CA, et al.  (2017). T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun
8:1747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5700944</ArticleId>
            <ArticleId IdType="pubmed">29170511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Fuchs HE, et al.  (2021). Cancer statistics, 2021. CA Cancer J Clin
71:7–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33433946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stultz J, Fong L. (2021). How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis
24:697–717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8384622</ArticleId>
            <ArticleId IdType="pubmed">33820953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tormoen GW, Crittenden MR, Gough MJ. (2018). Role of the immunosuppressive microenvironment in immunotherapy. Adv Radiat Oncol
3:520–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6200899</ArticleId>
            <ArticleId IdType="pubmed">30370351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wculek SK, Cueto FJ, Mujal AM, et al.  (2020). Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol
20:7–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31467405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You B, Xu W, Zhang B. (2018). Engineering exosomes: a new direction for anticancer treatment. Am J Cancer Res
8:1332–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6129493</ArticleId>
            <ArticleId IdType="pubmed">30210908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao SG, Lehrer J, Chang SL, et al.  (2019). The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst
111:301–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30321406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou ZX, Sun L. (2015). Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus). Dev Comp Immunol
49:113–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25475963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu H, Fang X, Zhang D, et al.  (2016). Membrane-bound heat shock proteins facilitate the uptake of dying cells and cross-presentation of cellular antigen. Apoptosis
21:96–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26481477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zininga T, Ramatsui L, Shonhai A. (2018). Heat shock proteins as immunomodulants. Molecules
23:2846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6278532</ArticleId>
            <ArticleId IdType="pubmed">30388847</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
